The stories behind three great LMB successes are highlighted in a report by the UK BioIndustry Association (BIA). Humira, the first fully humanised antibody and one of the worlds top selling drugs (pages 3-4), Lemtrada (CAMPATH) treatment for Multiple Sclerosis (pages 5-6) and the Stabilised GPCR StaR® technology which enables determination of receptor structures (pages 11-12) all came from work carried out at the LMB. To read about these stories and others, please download the pdf “Celebrating UK Bioscience“.
LMB contribution towards UK bioscience success illuminated
Cambridge scientists unlock cause of some types of infertility
LMB’s Melina Schuh, in collaboration with Bourn Hall Clinic, may have found the cause of some types of infertility, including recurrent miscarriage, after new research found some human eggs carry the wrong number of chromosomes. This article is no longer available from the source website: Cambridge News 19 June 2015
Sarah Teichmann receives EMBO Gold Award
The LMB congratulates former LMB Group Leader, Sarah Teichmann, on receiving the 2015 EMBO Gold Award. More…
Joan A. Steitz: A place in the lab, and in biochemistry history
The pioneering career of LMB Alumnus Joan Steitz, currently Sterling Professor of Molecular Biophysics and Biochemistry at Yale University is featured by CTNOW, looking at her work and how Joan’s time at the LMB studying ribosomes led to her important discoveries in RNA research. More…
ISCB Senior Scientist Award for Cyrus Chothia
A look at the career of LMB’s Cyrus Chothia and his work on the structures and functions of proteins, following announcement of his ISCB Senior scientist award. More…
New Approach To Control Enzyme Function In Cells
A new technique, devised by Jason Chin’s group, could make it easier to target and inhibit specific enzymes and other proteins in cells and to turn that regulation on and off at will with light. Bioorthogonal ligand tethering, or BOLT, has been used to create an inhibitor that can regulate the activity of a target enzyme selectively, an approach called iBOLT. More…